The LFB Group's substantial investments into research and development, in order to test the therapeutic value of certain proteins and to develop new therapeutic proteins, are the spearhead of our commitment in the field of rare diseases. Its active support for key players involved in this area is recognized in the scientific and medical world.  

LFB Group develops and offers therapeutic solutions for patients with rare diseases. Moreover, the LFB Group is one of the only pharmaceutical companies in the world to offer a therapeutic solution for coagulation factor XI deficiencies, a pure Von Willebrand factor and an Alpha-1 antitrypsin in France. Along these same lines, LFB’s commitment in this area is illustrated by its use of clinical trials to validate the therapeutic benefits of certain proteins, mainly for autoimmune diseases.

For several years, LFB Group has been developing support and actions to this end, including a partnership with Orphanet.